{"filing":{"accession_number":"0001437749-26-033290","cik":"0002124403","ticker":null,"company_name":"Vicore Pharma Holding AB","form":"6-K","filing_date":"2026-10-22","report_date":"2026-10-31","primary_document":"vcre20261022c_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2124403/000143774926033290/vcre20261022c_6k.htm"},"events":[{"id":37343,"run_id":34425,"accession_number":"0001437749-26-033290","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces a positive interim milestone in Vicore's Phase 2b ASPIRE clinical trial: the independent Data Monitoring Committee recommended the trial continue without modification following a pre-planned futility analysis, with no safety concerns identified. The trial remains on track for mid-2027 topline results. This is a material operational/clinical development event for a clinical-stage biopharmaceutical company, as it demonstrates progress toward a key regulatory milestone and affects investor assessment of the company's lead program viability and cash runway. The disclosure does not fit discrete event categories like earnings_release, ma_activity, or exec changes, but represents a material clinical/operational milestone that would affect a reasonable investor's view of the company's prospects.","company_name":"Vicore Pharma Holding AB","ticker":null,"filing_date":"2026-10-22","form":"6-K","submitted_at":null,"items":[{"id":42026,"accession_number":"0001437749-26-033290","item_number":"EX-99.1","item_title":"ex_1029869.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a positive interim milestone in Vicore's Phase 2b ASPIRE clinical trial: the independent Data Monitoring Committee recommended the trial continue without modification following a pre-planned futility analysis, with no safety concerns identified. The trial remains on track for mid-2027 topline results. This is a material operational/clinical development event for a clinical-stage biopharmaceutical company, as it demonstrates progress toward a key regulatory milestone and affects investor assessment of the company's lead program viability and cash runway. The disclosure does not fit discrete event categories like earnings_release, ma_activity, or exec changes, but represents a material clinical/operational milestone that would affect a reasonable investor's view of the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-22T21:16:42.721567+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42026,"accession_number":"0001437749-26-033290","item_number":"EX-99.1","item_title":"ex_1029869.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a positive interim milestone in Vicore's Phase 2b ASPIRE clinical trial: the independent Data Monitoring Committee recommended the trial continue without modification following a pre-planned futility analysis, with no safety concerns identified. The trial remains on track for mid-2027 topline results. This is a material operational/clinical development event for a clinical-stage biopharmaceutical company, as it demonstrates progress toward a key regulatory milestone and affects investor assessment of the company's lead program viability and cash runway. The disclosure does not fit discrete event categories like earnings_release, ma_activity, or exec changes, but represents a material clinical/operational milestone that would affect a reasonable investor's view of the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-22T21:16:42.721567+00:00","company_name":"Vicore Pharma Holding AB","ticker":null,"filing_date":"2026-10-22"}]}